Celegene Corp's drug Abraxane (paclitaxel protein-bound particles for injectable suspension) was found to be effective at improving overall survival among pancreatic cancer patients when combined with chemotherapy, according to results from the drug's phase III clinical trial. Even though Pancreatic cancer is a relatively uncommon form of cancer - making up only 2.1% cancer cases - it is one of the leading causes of cancer related deaths killing around 38,000 people in the U.S. every year...
More...
More...